$AVIR
Atea Pharmaceuticals, Inc.

2020 Q4 Form 10-Q Financial Statement

#000156459020056724 Filed on December 10, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2019 Q3
Revenue $48.63M $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $14.14M $4.030M $1.400M
YoY Change 987.69% 187.86%
% of Gross Profit
Research & Development $4.480M $13.60M $2.411M
YoY Change 28.0% 464.12%
% of Gross Profit
Depreciation & Amortization $0.00 $0.00 $0.00
YoY Change
% of Gross Profit
Operating Expenses $18.63M $17.63M $3.769M
YoY Change 296.38% 367.74%
Operating Profit -$17.63M -$3.769M
YoY Change 367.74%
Interest Expense $10.00K $10.00K $100.0K
YoY Change -90.0% -90.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income $20.66M -$17.62M -$3.600M
YoY Change -539.57% 389.5%
Income Tax
% Of Pretax Income
Net Earnings $20.66M -$17.62M -$3.632M
YoY Change -539.57% 385.19%
Net Earnings / Revenue 42.48%
Basic Earnings Per Share -$1.74
Diluted Earnings Per Share $250.6K -$1.74 -$0.04
COMMON SHARES
Basic Shares Outstanding 82.62M 10.11M
Diluted Shares Outstanding 10.11M

Balance Sheet

Concept 2020 Q4 2020 Q3 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $850.1M $105.4M
YoY Change
Cash & Equivalents $850.1M $105.4M $25.60M
Short-Term Investments
Other Short-Term Assets $7.500M $3.000M
YoY Change
Inventory
Prepaid Expenses
Receivables $5.800M
Other Receivables $0.00
Total Short-Term Assets $863.5M $108.4M
YoY Change 3841.02%
LONG-TERM ASSETS
Property, Plant & Equipment $48.00K $49.00K
YoY Change 17.07%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $107.0K $1.644M
YoY Change -12.3%
Total Long-Term Assets $155.0K $1.693M
YoY Change -4.91%
TOTAL ASSETS
Total Short-Term Assets $863.5M $108.4M
Total Long-Term Assets $155.0K $1.693M
Total Assets $863.6M $110.1M
YoY Change 3812.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $60.00K $4.476M
YoY Change -89.05%
Accrued Expenses $14.40M $6.300M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $315.8M $10.82M
YoY Change 12868.99%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $36.00K $56.00K
YoY Change -62.11%
Total Long-Term Liabilities $36.00K $56.00K
YoY Change -62.11%
TOTAL LIABILITIES
Total Short-Term Liabilities $315.8M $10.82M
Total Long-Term Liabilities $36.00K $56.00K
Total Liabilities $315.8M $10.87M
YoY Change 12383.44%
SHAREHOLDERS EQUITY
Retained Earnings -$65.16M -$85.82M
YoY Change 20.19%
Common Stock $82.00K $10.00K
YoY Change 720.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $547.8M -$76.51M -$45.09M
YoY Change
Total Liabilities & Shareholders Equity $863.6M $110.1M
YoY Change 3812.62%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2019 Q3
OPERATING ACTIVITIES
Net Income $20.66M -$17.62M -$3.632M
YoY Change -539.57% 385.19%
Depreciation, Depletion And Amortization $0.00 $0.00 $0.00
YoY Change
Cash From Operating Activities $318.5M -$9.500M -$3.700M
YoY Change -4290.79% 156.76%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 426.2M -900.0K 0.000
YoY Change
NET CHANGE
Cash From Operating Activities 318.5M -9.500M -3.700M
Cash From Investing Activities 0.000 0.000 0.000
Cash From Financing Activities 426.2M -900.0K 0.000
Net Change In Cash 744.7M -10.40M -3.700M
YoY Change -9898.68% 181.08%
FREE CASH FLOW
Cash From Operating Activities $318.5M -$9.500M -$3.700M
Capital Expenditures $0.00 $0.00 $0.00
Free Cash Flow $318.5M -$9.500M -$3.700M
YoY Change -4290.79% 156.76%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Small Business
EntitySmallBusiness
false
CY2020Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3030000
CY2020Q3 us-gaap Assets Current
AssetsCurrent
108413000
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
49000
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Trading Symbol
TradingSymbol
AVIR
dei Entity Registrant Name
EntityRegistrantName
ATEA PHARMACEUTICALS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-0574869
dei Entity Address Address Line1
EntityAddressAddressLine1
125 Summer Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02110
dei City Area Code
CityAreaCode
857
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39661
dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2019Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1887000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4028000
dei Entity Central Index Key
EntityCentralIndexKey
0001593899
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-36161000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
146000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-2193000
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
80529575
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10109847
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
122000
dei Local Phone Number
LocalPhoneNumber
284-8891
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
249000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
21910000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
41000
CY2019Q4 us-gaap Assets
Assets
22073000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
548000
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10109847
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24177000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6681000
dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
53070161
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10091100
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10091100
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
82616937
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
105383000
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21661000
us-gaap Profit Loss
ProfitLoss
-9379000
us-gaap Share Based Compensation
ShareBasedCompensation
450000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
13000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-38208000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
147000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-3554000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
-41615000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3178000
us-gaap Operating Expenses
OperatingExpenses
31677000
us-gaap Operating Expenses
OperatingExpenses
9859000
us-gaap Operating Income Loss
OperatingIncomeLoss
-31677000
us-gaap Operating Income Loss
OperatingIncomeLoss
-9859000
us-gaap Interest And Other Income
InterestAndOtherIncome
74000
us-gaap Interest And Other Income
InterestAndOtherIncome
480000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-290000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
4259000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
361000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21768000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34599000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
105490000
CY2020Q3 us-gaap Restricted Cash
RestrictedCash
107000
CY2019Q3 us-gaap Restricted Cash
RestrictedCash
107000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-17629000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3769000
CY2020Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
7000
CY2019Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
137000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-17622000
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1644000
CY2020Q3 us-gaap Assets
Assets
110106000
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
4476000
CY2020Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
6340000
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
10816000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2435000
CY2020Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
56000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
95000
CY2020Q3 us-gaap Liabilities
Liabilities
10872000
CY2019Q4 us-gaap Liabilities
Liabilities
2530000
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
175745000
CY2019Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
69114000
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
10000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
10000
CY2020Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
9295000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4632000
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-85816000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-54213000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-76511000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-49571000
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
110106000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
22073000
CY2020Q3 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
57932090
CY2019Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
33645447
CY2020Q3 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
48958829
CY2019Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
33645447
CY2020Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
48958829
CY2019Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
33645447
CY2020Q3 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
178106000
CY2019Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
70606000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13601000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2411000
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1358000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7500000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
17629000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
3769000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-3632000
us-gaap Net Income Loss
NetIncomeLoss
-31603000
us-gaap Net Income Loss
NetIncomeLoss
-9379000
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.74
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.36
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.13
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.93
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10109847
CY2019Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
0
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
0
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10091100
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10099134
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10091100
CY2019Q4 avir Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1326000
CY2020Q3 avir Accrued Professional Fees And Other Current
AccruedProfessionalFeesAndOtherCurrent
626000
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
822000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4238000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
157000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4636000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
157000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
-45090000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
189000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-3988000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-53370000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
27000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
209000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-9993000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-63127000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4238000
us-gaap Profit Loss
ProfitLoss
-31603000
us-gaap Share Based Compensation
ShareBasedCompensation
4636000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
13000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2781000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
41000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3689000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21787000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8886000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
21000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-21000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2000
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
106631000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
27000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1128000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
105530000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
83722000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8888000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25711000
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25604000
avir Equity Issuance Costs Included In Accounts Payable And Accrued Expenses
EquityIssuanceCostsIncludedInAccountsPayableAndAccruedExpenses
394000
us-gaap Nature Of Operations
NatureOfOperations
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">1. Nature of Business</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Background</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Atea Pharmaceuticals, Inc., together with its subsidiary Atea Pharmaceuticals Securities Corporation, is referred to on a consolidated basis as the &#8220;Company&#8221;.</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">The Company is a&#160;clinical-stage&#160;biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from&#160;life-threatening&#160;viral infections. </font></p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited consolidated financial statements are presented as of September 30, 2020 and for the three-month and nine-month periods then ended.&nbsp;&nbsp; As discussed further in Note 13, there were several material events that occurred after September 30, 2020 which are described below: </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Series D-1 Convertible Preferred Stock</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2020, the Company issued 8,973,261 shares of Series D-1 Convertible Preferred Stock at a purchase price of $11.98 per share for gross proceeds of $107,500 (the &#8220;Series D-1 Closing&#8221;).&nbsp;&nbsp;</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Roche License Agreement</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2020, the Company<font style="Background-color:#FFFFFF;color:#000000;"> entered into the Roche License Agreement, granting Roche an exclusive license to develop and commercialize AT-527 outside of the United States (other than for certain use in connection with the hepatitis C indication). The Company also granted Roche a global license to manufacture AT-527 and agreed that Roche would manufacture the global commercial supply of AT-527 for uses other than the hepatitis C indication. As part of the consideration, Roche agreed to pay the Company an upfront payment of $350,000 (the &#8220;Roche Upfront Payment&#8221;), which was received in November 2020. </font></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Initial Public Offering</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2020, the Company completed an initial public offering of its common stock (the &#8220;IPO&#8221;).&nbsp;&nbsp;In connection with the IPO, the Company issued 14,375,000 shares of its common stock, including the exercise in full of the underwriters&#8217; option to purchase up to 1,875,000 shares, at $24.00 per share for aggregate gross proceeds of $345,000 before deducting underwriting discounts and commissions of $24,150 and offering expenses of approximately $3,200.&nbsp;&nbsp;As a result of the IPO, all shares of Series A, B, C, D and D-1 convertible preferred stock converted into 57,932,090 shares of common stock. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Risks and Uncertainties</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to risks and uncertainties common to clinical stage biopharmaceutical companies. These risks include, but are not limited to, potential failure of preclinical and clinical studies, uncertainties associated with research and development activities generally, competition from technical innovations of others, dependence upon key personnel, compliance with governmental regulations, the need to obtain marketing approval for any product candidate that the Company may discover and develop, the need to gain broad acceptance among patients, payers and health care providers to successfully commercialize any product for which marketing approval is obtained and the need to secure and maintain adequate intellectual property protection for the Company&#8217;s proprietary technology and products. Further, the Company is currently dependent on third-party service providers for much of its preclinical research, clinical development and manufacturing activities. Product candidates currently under development will require significant amounts of additional capital, additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization. Even if the Company is able to generate revenues from the sale of its product candidates, if approved, it may not become profitable. If the Company fails to become profitable or is unable to sustain profitability on a continuing basis, then it may be unable to continue its operations at planned levels and be forced to reduce its operations. The Company is also subject to risks associated with the COVID-19 global pandemic, including actual and potential delays associated with certain of its ongoing and anticipated trials, and potential negative impacts on the Company&#8217;s business operations and its ability to raise additional capital to finance its operations. </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Through September 30, 2020, the Company financed its operations from the sale of convertible preferred stock. Since its inception, the Company has incurred recurring operating losses and negative cash flows from operations. As of September 30, 2020, the Company had an accumulated deficit of $85,816. The Company expects to continue to generate operating losses for the foreseeable future. The Company believes that its cash and cash equivalents of $105,383 as of September 30, 2020, together with the net proceeds from the Series D-1 Closing, the Roche Upfront Payment and the net proceeds from the IPO will be sufficient to fund its operations as currently planned through at least 2023. </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company may seek additional capital through one or more of a combination of financing through the sale of additional equity securities, debt financing, or funding in connection with any additional collaborative relationships it may enter into or other arrangements. There can be no assurance that the Company will be able to obtain such additional funding, on terms acceptable to the Company, on a timely basis or at all. The terms of any financing may adversely affect the holdings or the rights of the Company&#8217;s existing shareholders.</p>
CY2020Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
0
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
0
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2020Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
96609000
CY2019Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
21038000
CY2020Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
175000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
154000
CY2020Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
126000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
113000
CY2020Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
5000
CY2019Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
4000
CY2020Q3 avir Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
4892000
CY2019Q4 avir Accrued License Fees Current
AccruedLicenseFeesCurrent
200000
CY2019Q4 avir Accrued Professional Fees And Other Current
AccruedProfessionalFeesAndOtherCurrent
361000
us-gaap Lease Expiration Date1
LeaseExpirationDate1
2022-07-31
CY2020Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
85000
CY2020Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
340000
CY2020Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
200000
CY2020Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
625000
CY2020Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
70000
CY2019Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
70000
us-gaap Operating Lease Expense
OperatingLeaseExpense
211000
us-gaap Operating Lease Expense
OperatingLeaseExpense
211000
CY2020Q3 us-gaap Temporary Equity Value Excluding Additional Paid In Capital
TemporaryEquityValueExcludingAdditionalPaidInCapital
175745000
CY2020Q3 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
48958829
us-gaap Common Stock Voting Rights
CommonStockVotingRights
On all matters to be voted upon by the holders of common stock, holders of common stock are entitled to one vote per share.
CY2020Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
56475053
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3911633
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
3408861
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
18747
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
300000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7001747
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2857918
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
7001747
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.50
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.38
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.43
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
6.83
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.65
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.47
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
3.65
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y8M12D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y4M24D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y8M12D
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3915000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
22406000
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
15371000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
22406000
CY2020Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
14923000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y8M12D
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
450000
us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0

Files In Submission

Name View Source Status
0001564590-20-056724-index-headers.html Edgar Link pending
0001564590-20-056724-index.html Edgar Link pending
0001564590-20-056724.txt Edgar Link pending
0001564590-20-056724-xbrl.zip Edgar Link pending
avir-10q_20200930.htm Edgar Link pending
avir-20200930.xml Edgar Link completed
avir-20200930.xsd Edgar Link pending
avir-20200930_cal.xml Edgar Link unprocessable
avir-20200930_def.xml Edgar Link unprocessable
avir-20200930_lab.xml Edgar Link unprocessable
avir-20200930_pre.xml Edgar Link unprocessable
avir-ex311_11.htm Edgar Link pending
avir-ex312_10.htm Edgar Link pending
avir-ex321_9.htm Edgar Link pending
avir-ex322_8.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending